Dr. Ron Laufer is the head and Senior Managing Director of MedImmune Ventures, a $400M evergreen venture capital fund. The fund, which is a subsidiary of the AstraZeneca Group, invests in Biopharmaceutical, MedTech and Healthcare IT start-up companies in North America, Europe, Israel and Australia. An experienced healthcare investor, Ron started his career as a physician before moving into venture capital. He was a co-founder of Lilly Ventures, the venture capital arm of Eli Lilly & Company, and later a Managing Director at Visium Asset Management, a private healthcare-focused investment firm, before joining MedImmune Ventures in 2010. Ron received his B.Sci., M.D. and M.P.H. from Hebrew University, and an M.B.A. from the Harvard Business School. He is currently an adjunct Professor of business administration at the Kelley Business School of Indiana University.